Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q3
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29 Feb 24
8-K
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
18 Jan 24
8-K
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
5 Jan 24
8-K
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
9 Nov 23
8-K
PMV Pharmaceuticals Updated PC14586 Phase 1 Data
12 Oct 23
8-K
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference
11 Oct 23
8-K
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
10 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
28 Apr 23
Registration and prospectus
S-8
Registration of securities for employees
24 Jan 24
POS AM
Prospectus update (post-effective amendment)
1 Mar 23
POSASR
Automatic shelf registration (post-effective amendment)
1 Mar 23
S-8
Registration of securities for employees
24 Jan 23
S-8
Registration of securities for employees
24 Jan 22
S-3ASR
Automatic shelf registration
4 Oct 21
S-8
Registration of securities for employees
21 May 21
S-8
Registration of securities for employees
28 Sep 20
424B4
Prospectus supplement with pricing info
25 Sep 20
S-1/A
IPO registration (amended)
24 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
Other
EFFECT
Notice of effectiveness
1 May 23
EFFECT
Notice of effectiveness
25 Sep 20
CERT
Certification of approval for exchange listing
24 Sep 20
CORRESP
Correspondence with SEC
22 Sep 20
CORRESP
Correspondence with SEC
22 Sep 20
CORRESP
Correspondence with SEC
21 Sep 20
UPLOAD
Letter from SEC
17 Sep 20
CORRESP
Correspondence with SEC
11 Sep 20
CORRESP
Correspondence with SEC
4 Sep 20
UPLOAD
Letter from SEC
18 Aug 20
Ownership
SC 13G/A
JPMORGAN CHASE & CO
9 Apr 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Boxer Capital, LLC
14 Feb 24
SC 13G
ArrowMark Colorado Holdings LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
JPMORGAN CHASE & CO
23 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24